Navigation Links
Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
Date:1/5/2012

EAST BRUNSWICK, N.J., Jan. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Noble Financial Capital Markets Eighth Annual Equity Conference on Tuesday, January 17, 2012 at 10:00 AM Eastern Time.  The conference will be held at the Seminole Hard Rock Hotel in Hollywood, Florida.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT - GContact:  Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan information@savient.com 

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006 

 


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
2. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
3. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
4. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
5. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
6. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
7. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
8. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
10. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
11. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Bio-Techne Corporation has partnered with Brazil ... diagnostic tool for the veterinary market. The PARATEST ... the only non-toxic, biodegradable fixative available to the ... Bio-Techne,s Diagnostic Division in Devens, MA ... manufacturing, and packaging capabilities to bring this unique ...
(Date:3/1/2017)... Research and Markets has announced the addition of ... & Infectious Diseases" report to their offering. ... Did you know? - ... Genomic Health, Inc.. - Beijing Wantai Biological Pharmacy,s Beijing ... infectious diseases diagnostics in China . - MDxHealth ...
(Date:3/1/2017)... HOUSTON , March 1, 2017  The Welch ... funding for basic research, today announced that Drs. ... are the 2017 recipients of the Norman ... being recognized as ,rising stars, having contributed significant scientific ... the first time in the 15 years of the ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... ... of eating disorders, is pleased to announce the opening of residential services, in ... this week, Aloria Health will accept adult clients for residential treatment. , ...
(Date:3/1/2017)... , ... March 01, 2017 , ... Hennessey Performance (HPE) today announced its VelociRaptor 600 ... Ford EcoBoost 3.5L twin turbo V6 engine from 450 bhp and 510 lb-ft of torque ... a 0-60 mph time of just 4.2 seconds while running down the ¼ mile in ...
(Date:3/1/2017)... ... March 01, 2017 , ... Both incentives ... Supplemental Nutrition Assistance Program (SNAP) can reduce food insecurity. Findings are presented in ... the American Journal of Preventive Medicine . , Researchers examined data from two ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... the release of its 2017 update to Compass, the popular online learning ... advisors. , Suitable for standardizing both new-hire on-boarding and annual competency-validation, Compass ...
(Date:3/1/2017)... ... 01, 2017 , ... Award-winning medical group Allied Anesthesia today announced that, as ... nations, averaging more than one trip per year since 1998. Char was named the ... features the details of his charitable work. Char has been an Allied Anesthesiologist since ...
Breaking Medicine News(10 mins):